Makoto Nagano

Preparation and characterization of recombinant prolactin receptor extracellular domain from rat

Complementary (c)DNA of the extracellular domain of rat prolactin receptor (rPRLR-ECD) was cloned in the prokaryotic expression vector pTrc99A, and expressed in Escherichia coli following induction with isopropyl-b-D-thiogalactopyranoside. The expressed rPRLR-ECD protein, contained within the refractile body pellet was solubilized in 4.5 M urea, refolded and purified on a Q-Sepharose column by stepwise elution with NaCl. Only approximately 10% of the expressed protein refolded as a monomeric fraction, yielding 5-6 mg/l of induced culture. The purified protein was over 98% homogeneous, as shown by SDS-PAGE in the presence or absence of reducing agent, and by chromatography on a Superdex column. Its molecular mass, determined by SDS-PAGE in the absence of reducing agent, was 28 kDa, and by gel filtration, 25.6 kDa. Binding experiments indicated high affinity for bovine placental lactogen (bPL) and human growth hormone (hGH) as compared to ovine (o) or rat PRLs. Gel filtration was used to determine the stoichiometry of rPRLR-ECDs interaction with these hormones. At a 5 microM initial concentration of the hormones, formation of 2:1 (ECD:ligand) complexes was detected with bPL, hGH and oPRL whereas only 1:1 complex was formed with rPRL. Dilution (25-fold) of these complexes did not affect the stoichiometry with bPL, whereas with hGH a clear tendency towards dissociation of the initial 2:1 complex to 1:1 complex was observed. This tendency was even stronger in the case of oPRL. Although all four hormones exhibited nearly identical activities in the Nb2-11C lymphoma cell bioassay, the ability of the purified rat or rabbit PRLR-ECD to inhibit hormonal mitogenic activity generally reflected their affinity for the respective hormones. In view of these and former results, we suggest that unlike in the GH:GHR-ECD interaction, the inability of lactogenic hormones to form a 1:2 complex with soluble recombinant PRLR-ECDs does not necessarily predicts lack of biological activity.

High affinity neurotensin receptor mRNA distribution in rat brain and peripheral tissues

Neurotensin (NT) is widely distributed in the central nervous system (CNS) and peripheral tissues, and its actions are mediated by a specific family of G protein-coupled receptors. In this study, the authors have measured the levels of gene expression of the high-affinity neurotensin receptor (NTR) with quantitative reverse-transcriptase-polymerase chain reaction (RT-PCR).In the rat brain, the highest quantities of NTR mRNA were found in the ventral mesencephalon and in the hypothalamus. Surprisingly, almost identical quantities were detected in both structures, despite results fromin situ hybridization studies revealing a low expression of NTR mRNA in the hypothalamus. The RT-PCR data suggest that large scale NTR mRNA synthesis is occurring in restrictive hypothalamic nuclei. Intermediate levels of expression were detected in the prefrontal cortex and striatum, and scant levels in the cerebellum. In peripheral tissues, the highest levels of NTR mRNA were detected in the colon, followed by the liver, and then duodenum and pancreas.In this study, the sensitivity and the accuracy of the quantitative RT-PCR method provided the means to estimate the relative distribution of NTR mRNA between brain structures and peripheral tissues. Therefore, this study promotes a better understanding of the localization of NTR synthesis in relationship with the various physiological effects of NT.

Clinical variant of Tangier disease in Japan: mutation of the ABCA1 gene in hypoalphalipoproteinemia with corneal lipidosis

AbstractDespite progress in molecular characterization, specific diagnoses of disorders belonging to a group of in-herited hypoalphalipoproteinemias, i.e., apolipoprotein AI deficiency, lecithin-cholesterol acyltransferase deficiency, Tangier disease (TD), and familial high-density lipoprotein (HDL) deficiency, remain difficult on a purely clinical basis. Several TD patients were recently found to be homozygous for mutations in the ABCA1 gene. We have documented here a clinical variant of TD in a Japanese patient who manifested corneal lipidosis and premature coronary artery disease as well as an almost complete absence of HDL-cholesterol, by identifying a novel homozygous ABCA1 mutation (R1680W). We propose that patients with apparently isolated HDL deficiency who are found to carry ABCA1 mutations may in fact belong to a category of TD patients whose phenotypic features are only partially expressed, and that a number of hidden clinical variants of TD might exist among other HDL deficiency patients who have escaped correct clinical diagnosis.

Absence of a putative ATPGTP binding site in the rat prolactin receptor

Two types of the long form of the rat prolactin receptor have been identified by two independent groups. One type of receptor has a consensus sequence for a putative ATP/GTP binding site in the cytoplasmic domain, while the other does not. Since this site would confer kinase activity to the prolactin receptor and represent an important element in the process of signal transduction, we wanted to clarify this discrepancy. To that end, three procedures capable of detecting a point mutation were performed: Southern analysis of reverse transcribed polymerase chain reaction (PCR) products, allele-specific PCR, and S1 nuclease analysis. All results clearly indicated that the sequence for the putative ATP/GTP binding site does not exist in the prolactin receptor.